Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion NV – Additional Topline Data from Positive Phase 1 Trial with THR-687 in Patients with Diabetic Macular Edema (DME) to be Presented at the Upcoming Angiogenesis, Exudation, and Degeneration 2020 Conference

THR-687, a potent pan-RGD integrin inhibitor, holds potential to become a new standard of care for patients with DME
5 Feb 2020

Leuven, Belgium, 5 February 2020 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation therapies for patients with diabetic eye disease, today announces that a presentation of further data from a Phase 1 study with THR-687 in patients with diabetic macular edema (DME) will be given at the Angiogenesis, Exudation, and Degeneration 2020 conference being held on February 8, 2020, in Miami, US. 

The presentation will be made by Arshad Khanani, M.D., M.A., Director of Clinical Research at Sierra Eye Associates, Reno, Nevada, US, one of the investigators of the THR-687 Phase 1 study.

Details of the presentation are as follows:

Title:                 Results of a Phase 1 Study Using the Integrin Antagonist THR-687 in Patients with DME

Date/Time:        February 8; 5.08 pm EST

Session title:     Diabetes, Uveitis, and Retinal Degenerations

Press release attachment: 
Tags: 
THR-687